These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 11428815

  • 1. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M.
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
    Martikainen JA, Ottelin AM, Kiviniemi V, Gylling H.
    Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP, Buskens E, Koffijberg H, Algra A.
    Circulation; 2008 Jun 03; 117(22):2875-83. PubMed ID: 18506010
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A, Zethraeus N, Henriksson P.
    Int J Technol Assess Health Care; 2005 Jun 03; 21(2):180-6. PubMed ID: 15921057
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA, Simoons ML.
    Eur Heart J; 2001 May 03; 22(9):751-61. PubMed ID: 11350107
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
    Borgström F, Johnell O, Jönsson B, Zethraeus N, Sen SS.
    Bone; 2004 Jun 03; 34(6):1064-71. PubMed ID: 15193554
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y, Shimbo T, Tsujii S, Ishii H, Kondo H, Nakamura T, Nagata-Kobayashi S, Fukui T.
    Int J Cardiol; 2007 May 16; 118(1):88-96. PubMed ID: 16949690
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
    Lindgren P, Jönsson B, Yusuf S.
    J Intern Med; 2004 May 16; 255(5):562-70. PubMed ID: 15078498
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
    Rubió PP.
    Public Health; 1997 Jan 16; 111(1):33-40. PubMed ID: 9033222
    [Abstract] [Full Text] [Related]

  • 18. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.
    Circulation; 2007 May 08; 115(18):2398-409. PubMed ID: 17452609
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of hypolipidaemic drugs.
    Reckless JP.
    Postgrad Med J; 1993 May 08; 69 Suppl 1():S30-3. PubMed ID: 8497454
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.